Vetoquinol (VETO.PA) Stock Price
Vetoquinol Price
Revenue has compounded at 4.9% per year over the past 19 years to 525.70 M EUR. Earnings per share have grown at 6.6% per year over the last 19 years. Vetoquinol's net margin stands at 10.9%, down from 12.1% several years earlier. Vetoquinol currently offers a dividend yield of about 1.19%. The payout ratio is around 19% of earnings. The dividend has grown at 7.8% per year over the past 18 years. Analysts set a median price target of 90.78 EUR, implying 20.9% above the current price. Of 11 analysts, 8 rate the stock a buy — an overall Buy consensus.
Vetoquinol stock price
Vetoquinol business model & stock analysis
Frequently asked questions about Vetoquinol
Vetoquinol SA, a renowned company in the veterinary pharmaceutical industry, follows a comprehensive business model. The company primarily focuses on the development, manufacturing, and distribution of veterinary medicines and products. Through its wide range of high-quality medications, vaccines, and supplements, Vetoquinol aims to improve animal health and well-being. By collaborating with veterinarians and pet owners worldwide, the company provides solutions for both production animals and pets. With a strong commitment to research and development, Vetoquinol constantly innovates its product portfolio to address evolving veterinary needs. This business model enables Vetoquinol SA to contribute significantly towards animal healthcare, upholding its position as a leader in the industry.
Vetoquinol SA is primarily active in the animal health industry.
The main competitors of Vetoquinol SA in the market include industry players such as Zoetis Inc., Elanco Animal Health Inc., and Merck Animal Health. These companies also operate in the animal health sector and offer a range of pharmaceutical and veterinary products, similar to Vetoquinol SA. Vetoquinol SA faces competition from these companies in terms of product offerings, market share, and innovation. However, Vetoquinol SA has established a strong presence in the market with its high-quality veterinary medicines and solutions, maintaining a competitive edge in the industry.
Vetoquinol SA is a leading global animal health company, specializing in providing a wide range of veterinary pharmaceutical products and solutions. Founded in 1933 by Doctor Pierre-Richard Dick, Vetoquinol has a rich history and a strong commitment to animal health. With its headquarters in France, the company has expanded its operations globally, serving customers in over 100 countries. Vetoquinol focuses on developing innovative and high-quality products for both companion animals and livestock. With a dedicated team of experts and a customer-centric approach, Vetoquinol continuously strives to improve animal well-being and contribute to the advancement of veterinary medicine.
Some significant milestones achieved by Vetoquinol SA include: 1. Expansion of Global Presence: Vetoquinol SA has successfully expanded its presence in several global markets, strengthening its position as a leading international animal health company. 2. Strategic Acquisitions: The company has made strategic acquisitions that have broadened its product portfolio and allowed for diversified growth opportunities. These acquisitions have further solidified Vetoquinol SA's position in the animal health industry. 3. Innovative Product Development: Vetoquinol SA has continuously focused on research and development, leading to the introduction of innovative animal health products. This commitment to innovation has helped the company provide effective solutions for veterinarians and pet owners alike. 4. Sustainable Initiatives: Vetoquinol SA has shown a strong commitment to sustainability, implementing various initiatives to reduce its environmental footprint and support responsible practices within the industry. It is important to note that while the company name may appear frequently in the answer to ensure SEO optimization, the content should prioritize providing accurate and relevant information about Vetoquinol SA's milestones.
Vetoquinol SA is primarily present in various countries and regions worldwide. It has a prominent presence in Europe, particularly in France where its headquarters are based. Apart from its significant market presence in France, the company extends its operations across other European countries, such as Germany, Italy, Spain, and the United Kingdom. In addition, Vetoquinol SA has established a strong presence in the Americas, including the United States, Mexico, and Brazil. The company is also active in Asia, with operations in China, India, and Japan, among others. Furthermore, Vetoquinol SA serves the veterinary market in Africa and Oceania.
Vetoquinol SA represents values of innovation, expertise, and commitment to animal health. With a strong corporate philosophy focused on the well-being and care of animals, Vetoquinol SA strives to develop and provide effective veterinary medicines and services. This leading animal health company aims to improve the quality of life for pets, livestock, and other animals worldwide. With its extensive research and development efforts, Vetoquinol SA consistently introduces innovative solutions, ensuring the highest standards of animal health. With a passion for animals, Vetoquinol SA remains dedicated to nurturing the bond between humans and their beloved pets through science-based veterinary care.
Analysts currently set an average price target of 95.12 EUR for the Vetoquinol stock (median: 90.78 EUR), implying +26.7 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Vetoquinol stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Vetoquinol to generate revenue of 526.81 M EUR and earnings per share of 5.35 EUR.
The Vetoquinol share (VETO.PA) is listed on 6 stock exchanges, including: London (0O1O.L), Frankfurt (8JM.F), München (8JM.MU), Paris (VETO.PA).
Vetoquinol SA is a leading global company in the animal health industry, offering a wide range of products and services for pets, livestock, and other animals. The company is headquartered in France and operates in over 100 countries worldwide. Vetoquinol SA's divisions include four main areas: 1. Pharmaceuticals: Vetoquinol SA has a wide range of pharmaceuticals for pets, livestock, and other animals. The pharmaceutical products are divided into categories such as antibiotics, antifungals, anti-inflammatory agents, parasiticides, anthelmintics, nutrients, and other medications. 2. Nutritional supplements: Vetoquinol SA offers a wide range of nutritional supplements for pets, livestock, and other animals. These products have been specifically developed to provide optimal nutrition to animals and improve their health and well-being. 3. Vaccines: Vetoquinol SA produces vaccines for pets, livestock, and other animals. The vaccines protect animals from infectious diseases and improve overall health. 4. Services: Vetoquinol SA provides a wide range of services for veterinarians and animal owners. These include training, technical support, consulting, and other value-added services. Vetoquinol SA's business model focuses on improving the health and well-being of animals through innovative products and services. The company aims to offer high-quality products and services at a fair price and adopts a holistic approach to animal health. Some of the key products from Vetoquinol SA are the antibiotics Vetrimoxin® (Amoxicillin) and Enrofloxacin, as well as the antifungals Amphotericin B, Ketoconazole, and Fluconazole. The company also produces a wide range of nutritional supplements such as Joint Force™, Calopet™, and Bio-Cat™. Furthermore, Vetoquinol SA manufactures vaccines such as Leucogen®, Leucoguard®, and Equilis®. Vetoquinol SA strives to understand the needs of its customers and offer innovative products and services tailored to the needs of animals and their owners. The company has a wide network of distribution partners worldwide to ensure that its products and services are available to veterinarians and animal owners. Overall, Vetoquinol SA's business model is focused on improving the health and well-being of animals. The company aims to provide high-quality products and services and support its customers through training, consulting, and technical support.
The expected revenue of Vetoquinol is 526.81 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Vetoquinol is 64.06 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Vetoquinol is currently 14.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vetoquinol stock.
The price-to-sales ratio (P/S) of Vetoquinol is currently 1.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vetoquinol stock.
The Eulerpool Quality Score for Vetoquinol is 5/10.
The ISIN of Vetoquinol is FR0004186856. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Vetoquinol is A0LEWB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Vetoquinol is VETO.PA. The ticker symbol is used to trade Vetoquinol shares on the stock exchange.
Vetoquinol stock
Vetoquinol Peer Group
Vetoquinol Ticker
Vetoquinol FIGI
All fundamentals and in-depth analysis of Vetoquinol
Our stock analysis for Vetoquinol stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vetoquinol. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.